A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
[google_news title=”” keyword=”inflammatory arthritis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Inflammatory arthritis
- Researchers unveil unique autoantibody profiles in rheumatoid arthritis patientson May 2, 2024 at 6:42 am
Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease.
- Tips for living with arthritison May 2, 2024 at 12:25 am
Arthritis isn’t a single disease, but a term that refers to more than 100 conditions characterized by joint pain or joint disease, says the Arthritis Foundation. Arthritis is the leading cause of ...
- Columbia researchers uncover brain's ability to control inflammationon May 1, 2024 at 5:00 pm
Discovering ways to control this newfound brain circuit may lead to novel therapies for common auto-immune diseases such as rheumatoid arthritis, type I diabetes, multiple sclerosis, neurodegenerative ...
- Inflammation + Poverty = A recipe for dying youngon May 1, 2024 at 4:56 pm
There’s one test that some believe your doctor may be missing — one that could be life-saving for millions of people.
- New Brain Circuit Identified in Mice That Controls Body’s Inflammatory Reactionson May 1, 2024 at 4:01 pm
Future research could identify drugs that can target this newfound brain circuit to help treat a vast range of immune disorders and diseases.
- What Is Psoriatic Arthritis? 3 MDs Weigh Inon May 1, 2024 at 12:15 pm
About 30 percent of people with psoriasis will develop psoriatic arthritis. Here's what to know about symptoms and treatment.
- Scientists identify new brain circuit in mice that controls body's inflammatory reactionson May 1, 2024 at 11:50 am
The brain can direct the immune system to an unexpected degree, capable of detecting, ramping up and tamping down inflammation, shows a new study in mice.
- Four superfoods that can help reduce inflammation in the body, according to expertson May 1, 2024 at 9:24 am
The reason? Because turmeric has some well-researched anti-inflammatory properties that can help to reduce the aches and pains associated with arthritis, as well as soothing inflammatory skin issues ...
- Four of the best superfoods to help reduce inflammationon May 1, 2024 at 5:58 am
Inflammation can have a negative effect on our health, contributing to heart disease, cancer, stroke and diabetes ...
via Bing News